ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

ACS Did Not Sign Bumpers Letter

May 1, 1992

NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.

April 20, 2007

New Analyses of PCPT Give Stronger Justification Use of Finasteride To Prevent Prostate Cancer.

May 23, 2008

Letter: Legal Fund Seeks Support For Fisher

March 3, 1995

Center Program Move Definite; DCBD to Be Renamed

September 22, 1989

Canadian NCI Plans Review Of National Breast Screening Study

February 24, 1995